On Wednesday, Transgenomic Inc (NASDAQ:TBIO)’s shares inclined 4.37% to $2.15.
Transgenomic Inc (TBIO) declared that Katherine Richardson, PhD, Vice President of Research & Development, will deliver a keynote address on June 11, 2015 at the GTBio Cancer Markers & Liquid Biopsies Conference. In her talk, Dr. Richardson will highlight how Transgenomic’s breakthrough Multiplexed ICE COLD-PCR™ (MX-ICP) technology uniquely enables use of liquid biopsies and broader adoption of precision and personalized medicine.
In her talk, Dr. Richardson describes how Multiplexed ICE COLD-PCR preferentially amplifies sequence alterations in challenging samples, delivering unbiased enrichment of gene regions that allows determination of all point mutations and insertions/deletions using Sanger or next generation sequencing, or droplet digital PCR, at very high sensitivities-about 0.01% in samples with limited amounts of DNA, such as plasma from blood or fine needle aspirates. In addition, its multiplexed format allows sensitive detection and monitoring of all genetic alterations in multiple targets using a single DNA sample.
Transgenomic, Inc., a biotechnology company, engages in advancing personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and clinical and research services in the United States and internationally. It operates in two segments, Laboratory Services, and Genetic Assays and Platforms.
Orexigen Therapeutics, Inc. (NASDAQ:OREX)’s shares dropped -0.76% to $4.59.
Heather D. Turner gave notice of her resignation as Senior Vice President, General Counsel and Secretary of Orexigen Therapeutics, Inc. (OREX) Ms. Turner is relocating to the San Francisco Bay Area with her family. Chris Hazuka, Associate General Counsel, will assume the role of acting-General Counsel while the ongoing search for a replacement is accomplished. The Company anticipates the resignation to be effective on or about June 25, 2015.
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products in the United States. The company offers Contrave for the treatment of obesity. It has a partnership agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Contrave in Canada and Mexico. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California.
At the end of Wednesday’s trade, B2Gold Corp (NYSEMKT:BTG)‘s shares surged 0.61% to $1.64.
B2Gold Corp (BTG) will host its Annual General and Special Meeting of Shareholders on June 12, 2015 at 2:00pm PDT. The Company will also host a conference call and webcast in conjunction with the meeting. For details please see below:
B2Gold Corp., a mid-tier gold mining company, explores and develops mineral properties in Nicaragua, the Philippines, Namibia, Burkina Faso, and Chile. The company principally explores for gold, silver, and copper.
Clean Diesel Technologies, Inc. (NASDAQ:CDTI), ended its Wednesday’s trading session with 2.39% gain, and closed at $2.14.
Clean Diesel Technologies, Inc. (CDTI) declared that it is raising about $5.1 million in gross proceeds in an underwritten public offering of 2,500,000 common stock units at a purchase price of $2.05 per unit. Each unit will comprise of one share of the Company’s common stock and 0.2 of a warrant to purchase one share of common stock. The warrants are exercisable six months and one day after the date of issuance at an exercise price of $2.65 per share and will expire, unless exercised, five years from the date they first become exercisable.
The net proceeds from the sale of the shares and the related warrants, after deducting underwriting discounts, commissions and expense reimbursements and other estimated offering expenses payable by CDTi, will be about $4.5 million, which does not comprise any potential proceeds from the cash exercise of any warrants. CDTi intends to use the net proceeds from this offering (counting any resulting from the exercise of the warrants, if any) for general corporate purposes, counting, but not limited to, working capital, general and administrative expenses, capital expenditures, implementation of planned priorities, and as otherwise revealed in the prospectus supplement.
Clean Diesel Technologies, Inc. manufactures and distributes light duty vehicle catalysts and heavy duty diesel emissions control systems and products to automakers, distributors, integrators, and retrofitters in the United States, Canada, Sweden, and the United Kingdom. It operates through two divisions, Catalyst and Heavy Duty Diesel Systems. The Catalyst division develops and produces catalysts to reduce emissions from gasoline, diesel, and natural gas combustion engines.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
